Business Context and Reporting Period
This Form 8-K Current Report was filed by Akers Biosciences, Inc. (Ticker: AKER) on November 1, 2019. The company is an emerging growth company incorporated in New Jersey. The report details significant changes to the company's executive leadership and board of directors effective November 1, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Termination of CEO/Interim CFO: The Board provided 60 days' notice to terminate Howard R. Yeaton from his roles as Chief Executive Officer and interim Chief Financial Officer. The Board intends to negotiate an arrangement for Mr. Yeaton to continue serving as interim CFO, though no assurance of an agreement exists.
- Appointment of Executive Chairman: Christopher C. Schreiber, a current director, was appointed Executive Chairman of the Board and Principal Executive Officer, effective immediately. Consequently, Mr. Schreiber resigned from the Audit, Compensation, and Nominating and Corporate Governance Committees as he is no longer considered "independent."
- Committee Leadership Change: Joshua Silverman was appointed Chairman of the Compensation Committee to fill the vacancy left by Mr. Schreiber.
- New Board Appointment: Robert C. Schroeder was appointed as a new member of the Board and the Audit Committee. He will serve until the 2019 annual meeting of stockholders.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed is the uncertainty regarding the negotiation of a continued interim CFO role with the departing CEO, Mr. Yeaton. The filing explicitly states there were no disagreements between the Company and Mr. Yeaton regarding operations, policies, or practices.
Investor Verification Checklist
- Verify the status of negotiations for Mr. Yeaton's continued service as interim CFO.
- Confirm the timeline for the appointment of a permanent Chief Executive Officer.
- Review the biographical details and potential conflicts of interest for the new director, Robert C. Schroeder.
- Check subsequent filings for the appointment of a permanent Chief Financial Officer.